Glenmark gets final US nod for sclerosis treatment drug
Riluzole is indicated for treating amyotrophic lateral sclerosis and according to IMS Health data had sales of USD 64 million for year ended March 2013.
June 19, 2013 / 13:00 IST
Moneycontrol Bureau
Pharma major Glenmark's US generics arm has received final approval from the US Food and Drugs Administration to sell Riluzole tablets in 50 mg strength.Riluzole is indicated for the treatment of amyotrophic lateral sclerosis and Glenmark Generics Inc said it will start shipping the tablets immediately.Riluzole had sales of USD 64 million for the year ended March 2013, the company said on Wednesday, citing IMS Health data.Glenmark now has 86 products authorized for distribution in the US market and 52 ANDAs (abbreviated new drug applications) are pending approval with the country's drug regulator.Glenmark shares were trading up a little over 1 percent at Rs 580 on NSE in morning trade. Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
